Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvectis Pharma, Inc.

9.49
+0.64007.23%
Post-market: 9.490.00000.00%16:05 EDT
Volume:222.83K
Turnover:2.11M
Market Cap:221.99M
PE:-8.55
High:9.75
Open:9.17
Low:8.97
Close:8.85
Loading ...

Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage

MT Newswires Live
·
14 Nov 2024

Wall Street Set to Open Flat Thursday; Initial Jobless Claims Lower Than Forecast

MT Newswires Live
·
14 Nov 2024

BRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer

Reuters
·
14 Nov 2024

Nuvectis Pharma Inc - Additional Phase 1B Clinical Data Expected in Q2 2025

THOMSON REUTERS
·
14 Nov 2024

Nuvectis Pharma Reports Encouraging Nxp800 Interim Data Supporting Ongoing Enrollment in Phase 1B Study in Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer

THOMSON REUTERS
·
14 Nov 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

GlobeNewswire
·
14 Nov 2024

Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks
·
13 Nov 2024

Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress

TIPRANKS
·
06 Nov 2024

Nuvectis Pharma Q3 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Cash, Cash Equivalents, And Short-term Investments Were $17.2M

Benzinga
·
05 Nov 2024

BRIEF-Nuvectis Pharma Q3 Net Income USD -4.153 Million

Reuters
·
05 Nov 2024

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

THOMSON REUTERS
·
05 Nov 2024

Nuvectis Pharma Q3 Cash & Investments USD 17.2 Million

THOMSON REUTERS
·
05 Nov 2024

Press Release: Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Dow Jones
·
05 Nov 2024

Nuvectis Pharma (NVCT) Gets a Buy from Roth MKM

TIPRANKS
·
28 Oct 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Business Wire
·
28 Oct 2024

Nuvectis Pharma Announces Upcoming Presentations for Nxp900 at the 2024 Aacr-Nci-Eortc Symposium on Molecular Targets and Cancer Therapeutics

THOMSON REUTERS
·
23 Oct 2024